title: A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser.
abstract: BACKGROUND
  Postinflammatory hyperpigmentation (PIH) is the most common skin complication in Asians after invasive cosmetic treatments.
  
  
  OBJECTIVE
  To determine whether oral tranexamic acid (TA) reduces the incidence of PIH after Q-switched ruby laser (QSRL) treatment.
  
  
  METHODS
  Thirty-two Japanese women underwent QSRL treatment for senile lentigines on the face. They were randomly divided into two groups that did (n=15) and did not (n=17) receive oral TA treatment (750 mg/d) for the first 4 weeks after QSRL treatment. Nineteen participants had melasma-like maculae at baseline. Clinical and colorimetric assessments were performed at baseline and 2 and 4 weeks later.
  
  
  RESULTS
  Pigmentation was effectively treated using QSRL at 2 weeks, but PIH was frequently seen at 4 weeks. There was no significant difference in the incidence of PIH between participants who received oral TA and those who did not. The presence of melasma did not influence the effectiveness of the treatment.
  
  
  CONCLUSIONS
  Although oral TA has been reported to have depigmentation effects, it may not be effective for preventing PIH after QSRL. Considering the dosage and duration of treatment, an optimal protocol may be needed to induce the efficacy of this treatment to achieve the PIH-preventing effect of oral TA.
authors: Department of Plastic Surgery, University of Tokyo School of Medicine, Tokyo, Japan.
authors: Harunosuke
authors: H
authors: Kato
authors: Jun
authors: J
authors: Araki
authors: Hitomi
authors: H
authors: Eto
authors: Kentaro
authors: K
authors: Doi
authors: Rintaro
authors: R
authors: Hirai
authors: Shinichiro
authors: S
authors: Kuno
authors: Takuya
authors: T
authors: Higashino
authors: Kotaro
authors: K
authors: Yoshimura
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000209:etiology* / Q000517:prevention & control*; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control; D007564:Japan; D007834:Lasers / Q000009:adverse effects*; D008875:Middle Aged; D011446:Prospective Studies; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid